RxDoctor Payments Data

Kelly Burrough, NP

Nurse Practitioner · Indianapolis, INNPI 1144276890

Payments from drug & device makers

$2,520in general payments, 2019–2025

Across 139 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$404
  • Pfizer$386
  • Lilly USA, LLC$375
  • AstraZeneca$263
  • Abbott$141
  • Bayer$133
  • plus $818 from 18 others

What the payments were for

  • Food & beverage$2,520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,520 in reported general payments places this provider in the 85th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$44,175
Medicare patients
153
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide49$57,400
RexultiBrexpiprazole23$45,194
OzempicSemaglutide42$44,768
MounjaroTirzepatide28$35,856
JardianceEmpagliflozin28$32,204
EliquisApixaban25$25,253
JanuviaSitagliptin Phosphate14$19,568
Combivent RespimatIpratropium/Albuterol Sulfate11$9,089
Breo ElliptaFluticasone/Vilanterol16$8,242
Incruse ElliptaUmeclidinium Bromide11$3,829
ShingrixVaricella-Zoster Ge/As01b/Pf17$3,755
AbrysvoRsv Vacc, Pref A And Pref B/Pf11$3,552
Gabapentin132$2,254
Atorvastatin Calcium344$2,145
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$375$93,25677 claims
Otsuka America Pharmaceutical, Inc.Rexulti$122$45,19423 claims
Novo NordiskOzempic$404$44,76842 claims
Boehringer IngelheimJardiance, Combivent Respimat$86$41,29339 claims
PfizerEliquis, Abrysvo$386$28,80536 claims
MerckJanuvia$19$19,56814 claims
GSKBreo Ellipta, Incruse Ellipta, Shingrix$15$15,82644 claims
AbbVieSynthroid$99$68313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →